Review





Similar Products

generation formulations employing darpin designed ankyrin repeat protein based targeting ligands  (Acuitas Therapeutics)
86
Acuitas Therapeutics generation formulations employing darpin designed ankyrin repeat protein based targeting ligands
Generation Formulations Employing Darpin Designed Ankyrin Repeat Protein Based Targeting Ligands, supplied by Acuitas Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/pmc13022615-17-6-3?v=Acuitas+Therapeutics
Average 86 stars, based on 1 article reviews
generation formulations employing darpin designed ankyrin repeat protein based targeting ligands - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
protein ligand interactions  (Molecular Dynamics Inc)
86
Molecular Dynamics Inc protein ligand interactions
Protein Ligand Interactions, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/pm42286162-401-13-16?v=Molecular+Dynamics+Inc
Average 86 stars, based on 1 article reviews
protein ligand interactions - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
stable ligand protein complexes  (Molecular Dynamics Inc)
86
Molecular Dynamics Inc stable ligand protein complexes
Stable Ligand Protein Complexes, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/pm42277171-520-4-0?v=Molecular+Dynamics+Inc
Average 86 stars, based on 1 article reviews
stable ligand protein complexes - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
protein ligand systems  (Pinney Associates Inc)
86
Pinney Associates Inc protein ligand systems
Protein Ligand Systems, supplied by Pinney Associates Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/pm42160907-285-3-45?v=Pinney+Associates+Inc
Average 86 stars, based on 1 article reviews
protein ligand systems - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
ligand protein interactions  (Accelrys)
86
Accelrys ligand protein interactions
Left: Total potential energy of the system as a function of time (300 ns) for the DOR apo-like reference system and the five <t>ligand–protein</t> complexes. Right: Solute RMSD from the reference structure as a function of time (300 ns). Panels: ( a ) apo-like, ( b ) mequitazine, ( c ) mavorixafor, ( d ) buclizine, ( e ) harringtonine, and ( f ) aprepitant.
Ligand Protein Interactions, supplied by Accelrys, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/pmc13163808-245-0-5?v=Accelrys
Average 86 stars, based on 1 article reviews
ligand protein interactions - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
protein ligand docking maltoheptose glc7  (Glygen Corporation)
86
Glygen Corporation protein ligand docking maltoheptose glc7
Left: Total potential energy of the system as a function of time (300 ns) for the DOR apo-like reference system and the five <t>ligand–protein</t> complexes. Right: Solute RMSD from the reference structure as a function of time (300 ns). Panels: ( a ) apo-like, ( b ) mequitazine, ( c ) mavorixafor, ( d ) buclizine, ( e ) harringtonine, and ( f ) aprepitant.
Protein Ligand Docking Maltoheptose Glc7, supplied by Glygen Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/10__12688_slash_f1000research__173311__1-36-37-41?v=Glygen+Corporation
Average 86 stars, based on 1 article reviews
protein ligand docking maltoheptose glc7 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
recombinant cd40l protein  (R&D Systems)
94
R&D Systems recombinant cd40l protein
Left: Total potential energy of the system as a function of time (300 ns) for the DOR apo-like reference system and the five <t>ligand–protein</t> complexes. Right: Solute RMSD from the reference structure as a function of time (300 ns). Panels: ( a ) apo-like, ( b ) mequitazine, ( c ) mavorixafor, ( d ) buclizine, ( e ) harringtonine, and ( f ) aprepitant.
Recombinant Cd40l Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/pm42001092-134-44-47?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
recombinant cd40l protein - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
cd27  (R&D Systems)
94
R&D Systems cd27
Left: Total potential energy of the system as a function of time (300 ns) for the DOR apo-like reference system and the five <t>ligand–protein</t> complexes. Right: Solute RMSD from the reference structure as a function of time (300 ns). Panels: ( a ) apo-like, ( b ) mequitazine, ( c ) mavorixafor, ( d ) buclizine, ( e ) harringtonine, and ( f ) aprepitant.
Cd27, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/pm42001092-134-50-51?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
cd27 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
notch ligand dll4  (R&D Systems)
94
R&D Systems notch ligand dll4
(a) αSMA mRNA levels in HCAEC treated with TGFβ1 (10 ng/ml) or exposed to hypoxic conditions (5% O 2 ), in the absence or presence of moderate dose EtOH (25 mM, green bars) or high dose EtOH (100 mM, red bars) +/- the γ-secretase inhibitor DAPT (20 μM). (b) αSMA and fibronectin (FN) mRNA levels in HCAEC treated with TGFβ1 +/- the Notch ligand <t>DLL4</t> (3 μg/ml) in the absence or presence of DAPT (20 μM). Data are mean±SEM, n=3. *p<0.05 vs control (no treatment), #p<0.05 vs TGFβ1 or hypoxia.
Notch Ligand Dll4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+ligands/bio_rxiv__64898__2026__04__14__718463-41-15-23?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
notch ligand dll4 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

Image Search Results


Left: Total potential energy of the system as a function of time (300 ns) for the DOR apo-like reference system and the five ligand–protein complexes. Right: Solute RMSD from the reference structure as a function of time (300 ns). Panels: ( a ) apo-like, ( b ) mequitazine, ( c ) mavorixafor, ( d ) buclizine, ( e ) harringtonine, and ( f ) aprepitant.

Journal: International Journal of Molecular Sciences

Article Title: Structure-Guided Repurposing of Approved Drugs Identifies Aprepitant and Mavorixafor as Putative δ-Opioid Receptor Agonist Candidates

doi: 10.3390/ijms27093823

Figure Lengend Snippet: Left: Total potential energy of the system as a function of time (300 ns) for the DOR apo-like reference system and the five ligand–protein complexes. Right: Solute RMSD from the reference structure as a function of time (300 ns). Panels: ( a ) apo-like, ( b ) mequitazine, ( c ) mavorixafor, ( d ) buclizine, ( e ) harringtonine, and ( f ) aprepitant.

Article Snippet: Ligand-protein interactions were analyzed using BIOVIA Discovery Studio Visualizer (v. 25.1.0.24284, Dassault Systèmes Biovia Corp., San Diego, CA, USA) software.

Techniques:

(a) αSMA mRNA levels in HCAEC treated with TGFβ1 (10 ng/ml) or exposed to hypoxic conditions (5% O 2 ), in the absence or presence of moderate dose EtOH (25 mM, green bars) or high dose EtOH (100 mM, red bars) +/- the γ-secretase inhibitor DAPT (20 μM). (b) αSMA and fibronectin (FN) mRNA levels in HCAEC treated with TGFβ1 +/- the Notch ligand DLL4 (3 μg/ml) in the absence or presence of DAPT (20 μM). Data are mean±SEM, n=3. *p<0.05 vs control (no treatment), #p<0.05 vs TGFβ1 or hypoxia.

Journal: bioRxiv

Article Title: A Biphasic Effect of Alcohol on Endothelial Plasticity Through Regulation of Endothelial-to-Mesenchymal Transition

doi: 10.64898/2026.04.14.718463

Figure Lengend Snippet: (a) αSMA mRNA levels in HCAEC treated with TGFβ1 (10 ng/ml) or exposed to hypoxic conditions (5% O 2 ), in the absence or presence of moderate dose EtOH (25 mM, green bars) or high dose EtOH (100 mM, red bars) +/- the γ-secretase inhibitor DAPT (20 μM). (b) αSMA and fibronectin (FN) mRNA levels in HCAEC treated with TGFβ1 +/- the Notch ligand DLL4 (3 μg/ml) in the absence or presence of DAPT (20 μM). Data are mean±SEM, n=3. *p<0.05 vs control (no treatment), #p<0.05 vs TGFβ1 or hypoxia.

Article Snippet: Where indicated, cells were treated with Notch inhibitor DAPT (20 μM, Cat. #2634, Tocris,) or Notch ligand DLL4 (2 μg/ml, Cat. # 1506-D4, R&D Systems).

Techniques: Control